Effects of salicylate on 3,4-Methylenedioxymethamphetamine (MDMA)-induced neurotoxicity in rats

Pharmacology Biochemistry and Behavior

Volumn 58, Issue 3, 1997, Pages 701-708

  Yeh, S Y ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

3,4 Methylenedioxyamphetamine (MDA); 3,4 Methylenedioxymethamphetamine (MDMA); Hydroxyl radicals; Neurotoxicity; Salicylate; Superoxide radicals

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 5 HYDROXYINDOLEACETIC ACID; SALICYLIC ACID; SEROTONIN;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; HYPERTHERMIA; INTRAPERITONEAL DRUG ADMINISTRATION; LETHALITY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0030798269     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)90010-1     Document Type: Article

References (72)

1. 3H]paroxetine-labeled serotonin uptake sites J. Pharmacol. Exp. Ther. 242:1987;911-916.
2. Battaglia G., Yeh S. Y., De Souza E. B. MDMA-induced neurotoxicity. Parameters of degeneration and recovery of brain serotonin neurons Pharmacol. Biochem. Behav. 29:1988;269-274.
3. Brown C., Osterloh J. Multiple severe complications from recreational ingestion of MDMA ("Ecstasy"). JAMA. 258:1987;780-781.
4. Cadet J. L., Ladenheim B., Baum I., Calson E., Epstein C. CuZn-superoxide dismutase (CuZnSOD) transgenic mice show resistance to the lethal effects of methylenedioxyamphetamine (MDA) and of methylenedioxymethamphetamine (MDMA). Brain Res. 655:1994;259-262.
5. Cadet J. L., Ladenheim B., Hirata H., Rothman R., Ali S., Calson E., Epstein C., Moran T. H. Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (MDMA). Evidence from using CuZn-superoxide dismutase transgenic mice Synapse. 21:1995;169-176.
6. Cao W., Carney J. M., Duchon A., Floyd R. A., Chevion M. Oxygen free radical involvement in ischemia and reperfusion injury to brain. Neurosci. Lett. 88:1988;233-238.
7. Carney J. M., Starke-Reed P. E., Oliver C. N., Landum R. W., Cheng M. S., Wu J. F., Floyd R. A. Reversal of age-related increase in protein oxidation, decrease in enzyme activity, and loss in temporal and spatial memory by chronic administration of the spin-trapping compound N-tert-butyl-alpha-phenylnitrone. Proc. Natl. Acad. Sci. USA. 88:1991;3633-3636.
8. Castellano F. N., He Z., Greenaway F. T. Hydroxyl radical production in the reaction of copper-containing amine oxidases with substrates. Biochim. Biophys. Acta. 1157:1993;162-166.
9. Colado M. I., Green A. R. The spin trap reagent α-phenyl-N-tert-butyl nitrone prevents "Ecstasy"-induced neurodegeneration of 5-hydroxytryptamine neurones. Eur. J. Pharmacol. 280:1995;343-346.
10. Commins D. L., Vosmer G., Virus R. M., Woolverton W. L., Schuster E. R., Seiden L. S. Biochemical and histological evidence that methylenedioxymethamphetamine (MDMA) is toxic to neurons in the rat brain. J. Pharmacol. Exp. Ther. 241:1987;338-345.
11. Davis M. W., Hatoum H. T., Waters I. W. Toxicity of MDA (3,4-methylenedioxyamphetamine) considered for relevance to hazards of MDMA (Ecstasy) abuse. Alcohol Drug Res. 7:1987;123-134.
12. Dixon W. J., Brown M. B., Engelman L., Jennrich R. L. BMDP statistical software manual. 1990;University of California Press, Berkeley.
13. Elayan I., Gibb J. W., Hanson G. R., Foltz R. L., Lim H. K., Johnson M. Long-term alteration in the central monoaminergic systems of the rat by 2,4,5-trihydroxyamphetamine not by 2-hydroxy-4,5-methylenedixoymethamphetamine or 2-hydroxy-4,5-methylenedixoyamphetamine. Eur. J. Pharmacol. 221:1992;282-288.
14. Elayan I., Gibb J. W., Hanson G. R., Lim H. K., Foltz R. L., Johnson M. Long-term alteration in the central monoaminergic systems of the rat by 2,4,5-trihydroxyamphetamine, 2,4,5-trihydroxymethamphetamine and 3-4-dihydroxymethamphetamine on central tryptophan hydroxylase activity. J. Pharmacol. Exp. Ther. 265:1993;813-818.
15. Farfel G. M., Seiden L. S. Role of hypothermia in the mechanism of protection against serotonergic toxicity. I. Experiments using 3,4-methylenedioxymethamphetamine, dizocilpine, CGS 19755 and NBQX. J. Pharmacol. Exp. Ther. 272:1995;860-867.
16. Gibb J. W., Hanson G. R., Johnson M. Neurochemical mechanisms of toxicity. Cho A. K., Segal D. S. Amphetamine and its analogs. 1994;274-275 Academic Press, New York.
17. 3H]-DOPA in various regions of the brain. J. Neurochem. 13:1966;655-659.
18. Green A. R., Cross A. J., Goodwin G. M. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA) or "Ecstasy." Psychopharmacology. 119:1995;247-260.
19. Hardman H. F., Haavik C. O., Seevers M. H. Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals. Toxicol. Appl. Pharmacol. 25:1973;299-309.
20. Hasting T. G., Lewis D. A., Zigmond M. J. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl Acad. Sci. USA. 93:1996;1956-1961.
21. Henry J. A., Jeffreys K. J., Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("Ecstasy"). Lancet. 340:1992;384-387.
22. Hiramatsu M., Kumagai Y., Unger S. E., Cho A. K. Metabolism of methylenedioxymethamphetamine. Formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct J. Pharmacol. Exp. Ther. 254:1990;521-527.
23. Insel T. R., Battaglia G., Johannessen J. N., Marra S., De Souza E. B. 3,4-Methylenenedioxymethamphetamine ("Ecstasy") selectively destroys brain serotonin terminals in rhesus monkeys. J. Pharmacol. Exp. Ther. 249:1989;713-720.
24. Johnson M., Elayer I., Hanson G. R., Foltz R. L., Gibb J. W., Lim H. K. Effects of 3,4-dihydroxymethamphetamine and 2,4,5-trihydroxymethamphetamine, two metabolites of 3,4-methylenedioxymethamphetamine, on central serotonergic and dopaminergic systems. J. Pharmacol. Exp. Ther. 261:1992;447-453.
25. Kadiiska M. B., Hanna P. M., Hernandez L., Mason R. P. In vivo evidence of hydroxy radical formation after acute copper and ascorbic acid intake. Electron spin resonance spin-trapping investigation Mol. Pharmacol. 42:1992;723-729.
26. Kadiiska M. B., Hanna P. M., Jordan S. J., Mason R. P. Electron spin resonance evidence for free radical generation in copper-treated vitamin E- and selenium-deficient rats. In vivo spin-trapping investigation Mol. Pharmacol. 44:1993;222-227.
27. Kleven M. S., Woolverton W. L., Seiden L. S. Evidence that both intragastic and subcutaneous administration of methylenedioxymethamphetamine (MDMA) produce serotonin neurotoxicity in rhesus monkeys. Brain Res. 488:1989;121-125.
28. Knecht K. T., DeGray J. A, Mason R. P. Free radical metabolism of halothane in vivo:radical adducts detected in bile. Mol. Pharmacol. 41:1992;943-949.
29. Komarov A., Mattson D., Jones M. M., Singh P. K., Lai C. S. In vivo spin trapping of nitric oxide in mice. Biochem. Biophys Res. Commun. 195:1993;1191-1198.
30. Kubow S., Janzen E. G., Bray T. M. Spin-trapping of free radicals formed in vitro and in vivo metabolism of 3-methylindole. J. Biol. Chem. 259:1984;4447-4451.
31. Kumagai Y., Lin L. Y., Schmitz D. A., Cho A. K. Hydroxyl radical mediated demethylenation of (methylenedioxy)phenyl compounds. Chem. Res. Toxicol. 4:1991;330-334.
32. Lai E. K., Crossley C., Sridhar R., Misra H. P., Janzen E. G., McCay P. B. In vivo spin trapping of free radicals generated in brain, spleen, and liver during gamma radiation of mice. Arch. Biochem. Biophys. 244:1986;156-160.
33. Lenge R. E. The Sigma-Aldrich library of chemical safety data. 2:1988;Sigma-Aldrich Co, Milwaukee, WI. 3065.
34. Lim H. K., Foltz R. L. In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in the rat. Identification of metabolites using an ion trap detection Chem. Res. Toxicol. 1:1988;370-378.
35. Lim H. K., Foltz R. L. In vivo formation of aromatic hydroxylated metabolites of 3,4-(methylenedioxy)methamphetamine in the rat. Identification by ion trap tandem mass spectrometric (MS/MS and MS/MS/MS) techniques Biol. Mass Spectrometr. 20:1991;677-686.
36. Lim H. K., Foltz R. L. Ion trap tandem mass spectrometric evidence for the metabolism of 3,4-(methylenedioxy)methamphetamine to the potent neurotoxins 2,4,5-trihydroxymethamphetamine and 2,4,5-trihydroxyamphetamine. Chem. Res. Toxicol. 4:1991;626-632.
37. Lin L. Y., Kumagai Y., Cho A. K. Enzymatic and chemical demethylation of (methylenedioxy)amphetamine and (methylenedioxy)methamphetamine by rat brain microsomes. Chem. Res. Toxicol. 5:1992;401-406.
38. Liu Z. C., McCleland R. A., Uetrecht J. P. Oxidation of 5-aminosalicylic acid by hypochlorous acid to a reactive iminoquinone. Drug Metab. Disp. 23:1995;246-250.
39. Lloyd R. V., Shuster L., Mason R. P. Reexamination of the microsomal transformation of N-hydroxynorcocaine to norcocaine nitroxide. Mol. Pharmacol. 43:1993;645-648.
40. Malberg J. E., Sabot K. E., Seiden L. S. Coadministration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. J. Pharmacol. Exp. Ther. 278:1996;258-267.
41. Midha K. K., Copper J. K., By A., Ethier J.-C. Identification of 3,0-methyl-alpha-methyldopamine as a urinary metabolite of 3,4-methylenedioxyamphetamine in dog and monkey. Drug Metab. Disp. 5:1977;143-148.
42. Midha K. K., Hubbard J. W., Bailey K., Copper J. K. α-Methyldopamine, a key intermediate in the metabolic disposition of 3,4-methylenedioxyamphetamine in vivo in dog and monkey. Drug Metab. Disp. 6:1978;623-630.
43. Miller R. T., Lau S. S., Monks T. J. Metabolism of 5-(glutathion-S-yl)-α-methyldopamine following intracerebroventricular administration to male Sprague-Dawley rats. Chem. Res. Toxicol. 8:1995;634-641.
44. Miller R. T., Lau S. S., Monks T. J. Effects of intracerebroventricular administration of 5-(glutathion-S-yl)-α-methyldopamine on brain dopamine, serotonin, and norepinephrine concentrations in male Sprague-Dawley rats. Chem. Res. Toxicol. 9:1996;457-465.
45. Miller D. B., O'Callaghan J. P. Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exp. Ther. 270:1994;752-760.
46. Miyajima T., Kotake Y. Spin trapping agent, phenyl N-tert-butyl nitrone, inhibits induction of nitric oxide synthase in endotoxin-induced shock in mice. Biochem. Biophys. Res. Commun. 215:1995;114-121.
47. Molliver M. E., Berger U. V., Mamounas L. A., Moliver D. C., O'Hearn E., Wilson M. Neurotoxicity of MDMA and related compounds. Anatomic studies Whitaker-Azmitia P. M., Peroutka S. J. The neuropharmacology of serotonin. 1990;640-664 New York Academy of Sciences, Annals of the New York Academy of Sciences, vol. 600. New York.
48. Newcomer T. A., Palmer A. M., Rosenberg P. A., Aizenman E. Nonenzymatic conversion of 3,4-dihydroxyphenylalanine to 2,4,5-trihydroxyphenylalanine and 2,4,5,-trihydoxyphenylalanine quinone in physiological solutions. J. Neurochem. 61:1993;911-919.
49. Paris J. M., Cunningham K. A. Lack of serotonin neurotoxicity after intraraphe microinjection of (+)-3,4-methylenedioxymethamphetamine (MDMA). Brain Res. Bull. 28:1991;115-119.
50. Paolini M., Sapigni E., Mesirca R., Pedulli G. F., Corongiu F. P., Dessi M. A., Cantelli-Forti G. On the hepatotoxicity of 1,1,2,2 tetrachloroethane. Toxicology. 73:1992;101-115.
51. Poyer J. L., McCay P. B. In vivo spin-trapping of radicals formed during halothane metabolism. Biochem. Pharmacol. 29:1981;2566-2570.
52. Ricaurte G. A., Martello A. L., Katz J. L., Martello M. B. Lasting effects of (+/-)-3,4-methylenenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates. Neurochemical observations J. Pharmacol. Exp. Ther. 261:1992;616-622.
53. Schmidt C. J. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 240:1987;1-7.
54. Schmidt C. J. Neurotoxicity of ring-substituted amphetamine analogs. Cho A. K., Segal D. S. Amphetamine and its analogs. 1994;153 Academic Press, New York.
55. Schmidt C. J., Kehne J. H. Neurotoxicity of MDMA. Neurochemical effects Whitaker-Azmitia P. M., Peroutka S. J. The neuropharmacology of serotonin. 1990;665-681 New York Academy of Sciences, Annals of the New York Academy of Sciences, vol. 600. New York.
56. Schmidt C. J., Taylor V. L. Direct central effects of acute methylenenedioxymethamphetamine on serotonergic neurons. Eur. J. Pharmacol. 156:1988;121-131.
57. Schmidt C. J., Black C. K., Taylor V. L. Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine. Eur. J. Pharmacol. 181:1990;59-70.
58. 2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking acute stimulation of dopamine synthesis. Reversal by L-dopa J. Pharmacol. Exp. Ther. 256:1991;230-235.
59. Schulz J. B., Henshaw D. R., Matthews R. T., Beal M. F. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Exp. Neurol. 132:1995;279-283.
60. Sentjurc M., Mason R. P. Inhibition of radical adduct reduction and reoxidation of the corresponding hydroxylamines in in vivo spin trapping of carbon tetrachloride-derived radicals. Free Rad. Biol. Med. 13:1992;151-160.
61. Sloot W. N., Gramsbergen J. B. P. Detection of salicylate and its hydroxylated adducts 2,3- and 2,5-dihydroxybenzoic acids as possible indices for in vivo hydroxyl radical formation in combination with catechol- and indoleamines and their metabolites in cerebrospinal fluid and brain tissue. J. Neurosci. Methods. 60:1995;141-149.
62. Sprague J. E., Nichols D. E. The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedixoymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J. Pharmacol. Exp. Ther. 273:1995;667-673.
63. Stone D. M., Johnson M., Hanson G. R., Gibb J. W. Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 247:1988;79-87.
64. Stone D. M., Johnson M., Hanson G. R., Gibb J. W. Acute inactivation of tryptophan hydroxylase by amphetamine anlogs involves the oxidation of sulfhydryl sites. Eur. J. Pharmacol. 172:1989;93-97.
65. Tanigawa T., Kotake Y., Reinke L. A. Spin trapping of superoxide radicals following stimulation of neutrophils with fMLP is temperature dependent. Free Rad. Biol. Med. 15:1993;425-433.
66. Tabatabaie T., Floyd R. A. Susceptibility of glutathione peroxidase and glutathione reductase to oxidative damage and the protective effect of spin trapping agents. Arch. Biochem. Biophys. 314:1994;112-119.
67. Wink D. A., Nims R. W., Saavedra J. E., Utermahlen W. E. Jr., Ford P. C. The Fenton oxidation mechanism. Reactivities of biologically relevant substrates with two oxidizing intermediates differ from those predicted for the hydroxyl radical Proc. Natl. Acad. Sci. USA. 91:1994;6604-6608.
68. Yeh S. Y. Protection of 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity by phenyl-t-butylnitrone (PBN), but not by salicylate (SALI), in rats. Soc. Neurosci. Abstr. 25:1995;973.
69. Yeh, S. Y.: N-tert-butyl-α-phenylnitrone (PBN) protects against 3,4-methylenedioxymethamphetamine (MDMA)-induced neurotoxicity in rats. Submitted for review.
70. Yeh S. Y., Hsu F. L. The neurochemical and stimulatory effects of putative metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine in rats. Pharmacol. Biochem. Behav. 39:1991;787-790.
71. Yousif M. Y., Fitzgerald R. L., Narasimhachari N., Rosecrans J. A., Blanke R. V., Glennon R. C. Identification of metabolites of 3,4-methylenedioxymethamphetamine in rats. Drug Alcohol Depend. 26:1990;127-135.
72. Zhao Z., Castignoli N., Ricaurte G. A., Steele T., Martello M. Synthesis and neurotoxicological evaluation of putative metabolites of the serotonergic neurotoxin 2-(methylamino)-1-[3,4-[methylenedioxy)phenyl]propane[(methylenedioxy) methamphetamine.Chem. Res. Toxicol. 5:1992;89-92.